14 December 2017 EMA/CHMP/413341/2017

Work plan for the Oncology Working Party (ONCWP) for 2018

Chairperson: Pierre Demolis Status of the work plan: December 2017 – Adopted The activities outlined in the work plan for 2018 have been agreed considering the respective business priorities, as well as the Agency’s relocation as a result of the UK’s exit from the EU and its impact on the Agency’s business continuity, and may be subject to further review and reprioritisation in accordance with the business continuity plan of the Agency.

1. Meetings scheduled for 2018 Meetings are planned for the following dates: •

January (virtual meeting*)



February (virtual meeting)



March (virtual meeting)



April (virtual meeting)



April 2018 – face to face meeting



May (virtual meeting)



June (virtual meeting)



July (virtual meeting)



September (virtual meeting)



September 2018– face to face meeting



October (virtual meeting)



November (virtual meeting)

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.



December (virtual meeting)

*Virtual meetings are to be followed by the international Oncology Cluster TCs – dates to be agreed with FDA The above mentioned dates may be modified as needed. Additional virtual meetings may be organised ad-hoc to respond to time-sensitive requests on products and to progress guidelines, as required.

2. Guidelines 2.1. New EU Guidelines Action: Lead The use of minimal residual disease as an endpoint in clinical trials in multiple myeloma Target date

Draft to be released for public consultation Q1 2018 Final to be published Q4 2018

Comments

To be included in the Annex 4 (Disease specific guidance) to the Note for Guidance on the Evaluation of anticancer medicinal products in man CHMP/205/95

2.2. EU Guidelines under revision Action: Lead Note for Guidance on the Evaluation of anticancer medicinal products in man, CHMP/205/95 Rev. 5 Target date Comments

Draft Revision 6 of the guidance to be released for public consultation Q3 2018 Comments received during the public consultation for rev.5 trigger further updates. Revisions will focus on New clinical endpoints; Biomarkers; Interim Analysis and data maturation; Estimands in Oncology. BSWP position on “Methods on treatment cross-over for time-to-event endpoints in oncology clinical trials”; Integration of information on paediatric requirements.

Revision of the addendum to the guideline on evaluation of anticancer medicinal products in man paediatric oncology, CPMP/EWP/569/02 Rev. 2 Target date

Draft addendum to be released by Q3 2018 – in line with revision 6.

Comments

Update of the paediatric guidance in oncology was foreseen during Rev.4 of the Note for Guidance on the evaluation of anticancer medicinal products in man CHMP/205/95.

Work plan for the Oncology Working Party (ONCWP) for 2018 EMA/CHMP/413341/2017

Page 2/4

2.3. ICH Guidelines ICH S9 Q&A: Nonclinical Evaluation for Anticancer Pharmaceuticals— Questions and Answers Target date

Step 4 planned for Q1 2018

Comments

Ongoing drafting work to address public comments received. ONCWP to review the updated document.

3. Medicinal Products-specific activities 3.1. Pre-Authorisation activities •

Contribution to the scientific advice and protocol assistance provided by the SAWP upon request of SAWP.



Recommendation to the CAT on data submitted to the Agency for scientific evaluation of the clinical data of an ATMP (Art. 18 of Regulation (EC) 1394/2007).



Contribution to the Innovation Task Force.



Contribution to paediatric investigation plans (PIP) upon request of PDCO.

3.2. Evaluation and supervision activities •

Contribution/recommendation to CHMP marketing authorisation or post-authorisation evaluation procedures upon request of CHMP.



Input on non-centralised products (NAPs) evaluation/referral procedures upon request of the CMDh.



Contribution to referral discussions upon request from CHMP/PRAC.



Input into discussion of pharmacovigilance issues upon request from CHMP/PRAC.

4. Input in European activities 4.1. Training for the network and knowledge building Assessors’ training; On line training on the assessment of survival – in collaboration with the BSWP.

Work plan for the Oncology Working Party (ONCWP) for 2018 EMA/CHMP/413341/2017

Page 3/4

5. Input in International activities (beyond ICH guidelines) 5.1. Activities with other regulators International Oncology cluster Monthly teleconferences and joint activities with FDA, HC, PMDA, TGA, Swissmedic.

6. Contribution to dialogue and engagement with stakeholders and external parties 6.1. Workshops •

EMA- EORTC meeting on Health related Quality of life – date tbc (estimated March 2018) Workshop planned with the EORTC in Q4 2017. The EORTC having recognised the need for more agility of using QoL and PROs in clinical research, has transformed its ‘core questionnaire’, the EORTC QLQ-C30 into computer-adaptive testing (CAT). Another approach allowing more dynamic assessment is the use an item library to supplement the standardized (‘static’) instruments. The purpose of the workshop is to discuss optimal validation approaches of the new QoL instruments with the various stakeholders.



ONCWP workshop in Single Arm trials – date to be confirmed (estimated April 2018) This is a follow up to the EMA / ESMO Rare cancers initiative in 2015 and Single arm trials workshop in 2016 –A workshop is being planned with the aim to provide guidance.

In addition to the actions identified above, the working party can be involved in any other activities foreseen in its mandate: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/08/WC500095453.pdf

Work plan for the Oncology Working Party (ONCWP) for 2018 EMA/CHMP/413341/2017

Page 4/4

ONCWP Work plan 2018 - European Medicines Agency - Europa EU

Dec 14, 2017 - Send a question via our website www.ema.europa.eu/contact ... ad-hoc to respond to time-sensitive requests on products and to progress guidelines, as required. 2. Guidelines. 2.1. New EU Guidelines ... Recommendation to the CAT on data submitted to the Agency for scientific evaluation of the clinical.

133KB Sizes 44 Downloads 218 Views

Recommend Documents

PRAC Work Plan 2018 - European Medicines Agency - Europa EU
Jan 31, 2018 - Activities in 2018. PRAC activities to achieve the objectives set for this area: •. Review of lessons learnt from the pilot regulatory network study involving EMA, Spain and the United Kingdom, as a source of learnings for regulatory

Action plan - European Medicines Agency - Europa EU
5 days ago - Guidelines should include more details on the principles of good information design in which content and layout are ... relevance and importance of the QRD template is also acknowledged in this respect as it is the main tool .... databas

BSWP Work Plan 2017 - European Medicines Agency - Europa EU
Jan 26, 2017 - different aspects, or if these aspects call for the development of new ... Joint EMA Symposium in the margins of the CEN-ISBS conference, ...

COMP work plan 2017 - European Medicines Agency - Europa EU
Feb 15, 2017 - Improve the quality of initial orphan designation applications by ... Maintenance ... Development of strategies to implement recommendations ...

CAT work plan 2017 - European Medicines Agency - Europa EU
Apr 12, 2017 - Member. Marc Turner. Scottish National Blood Transfusion. Service .... CAT will collaborate with the BWP and the HMA innovation network on this ... 1.3.3. Addressing the Environmental Risk assessment of ATMPs containing.

PDCO work plan 2017 - European Medicines Agency - Europa EU
Jan 27, 2017 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union. Telephone +44 (0)20 3660 .... best available scientific expertise in the Network and ensure that paediatric information related

March 2018 - European Medicines Agency - Europa EU
Mar 15, 2018 - (Article 5(12) (b) of Regulation (EC) No 141/2000 of the European Parliament and of the Council). When a designated orphan medicinal product receives a positive opinion for marketing authorisation from EMA's Committee for Medicinal Pro

RadDG Work plan 2017 - European Medicines Agency - Europa EU
Dec 15, 2016 - Work plan for the Radiopharmaceutical Drafting Group for. 2017. Chairperson: Anabel Cortes Blanco. Status of the work plan: Adopted in ...

February 2018 - European Medicines Agency - Europa EU
Feb 27, 2018 - Tazemetostat for treatment of follicular lymphoma, Quintiles Ireland Limited. 2. Opinions adopted at the first COMP discussion: •. Docosahexaenoic acid ethyl ester for treatment of sickle cell disease, TurnKey PharmaConsulting. Irela

January 2018 - European Medicines Agency - Europa EU
Feb 8, 2018 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. Telephone +44 (0)20 3660 6000 ... This document provides current information related to the volume and evaluation of marketing authorisation and ... The purpose

March 2018 - European Medicines Agency - Europa EU
Mar 5, 2018 - it includes the INN (active moiety only, with no information on salt, ester or derivative) and therapeutic area. This list only includes information for medicines whose applications have been validated at the time the report was compile

July 2018 - European Medicines Agency - Europa EU
Jul 12, 2018 - An agency of the European Union ... This list only includes information for medicines whose applications have been validated at the time the.

June 2018 - European Medicines Agency - Europa EU
Jun 22, 2018 - An agency of the European Union. Telephone +44 (0)20 ... Selumetinib for treatment of neurofibromatosis type 1, AstraZeneca AB;. •. Synthetic ...

HMPC work plan 2015 - European Medicines Agency - Europa EU
Jan 30, 2018 - HMPC work plan. EMA/HMPC/150152/2018. Page 2/7. Evaluation activities for herbal medicinal products as defined in Reg. (EC) No 726/2004 and Dir. 2001/83/EC. 1.1. Establishment and update of EU herbal monographs and list entries. Activi

Agenda - European Medicines Agency - Europa EU
Jul 7, 2017 - COMMUNITY MARKETING AUTHORISATIONS AND EXTENSIONS. 2.1. Opinions ... Quality. Rapp: E. Werner .... solutions table with EMA and CVMP responses to the recommendations made by the FishMed Plus. Coalition ...

May 2016 - European Medicines Agency - Europa EU
Jun 22, 2016 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

Eleclazine - European Medicines Agency - Europa EU
Feb 9, 2017 - Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply).

July 2017 - European Medicines Agency - Europa EU
Jul 5, 2017 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

July 2016 - European Medicines Agency - Europa EU
Jul 4, 2016 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

SME Office - European Medicines Agency - Europa EU
maximises the chances of a successful marketing authorisation. ... marketing authorisation. • inclusion in the public SME ... E-mail [email protected]. Website ...

Agenda - European Medicines Agency - Europa EU
Jun 19, 2017 - and may also vary during the course of the review. ...... ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus ..... adjunctive administration of brivaracetam, Treatment of paediatric patients with partial.

Agenda - European Medicines Agency - Europa EU
Jun 15, 2016 - Agenda - EMA Human Scientific Committees' Working. Parties with Healthcare Professionals' Organisations. (HCPWP) meeting. 15 June 2016, 08:45hrs to 10:30hrs – meeting room: 3E. Chairs: I. Moulon (EMA) and Gonzalo Calvo (HCPWP). 15 Ju

Agenda - European Medicines Agency - Europa EU
Jun 26, 2018 - oxadiazole-3-carboximidamide - EMEA-002072-PIP01-16-M01 . ..... Human alpha-galactosidase A - Orphan - EMEA-001828-PIP01-15-M01 .

Agenda - European Medicines Agency - Europa EU
Jul 16, 2018 - Cladribine, EMA/OD/087/17 Recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8. 2.2.6. - EMA/OD/098/18. Treatment of ...